Published in Eur Respir J on May 01, 2006
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet (2012) 2.14
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemp Clin Trials (2009) 1.53
Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. PLoS Genet (2015) 1.38
Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable Cystic Fibrosis patients. Respir Res (2010) 1.07
Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatr Pulmonol (2010) 0.87
Pseudomonas infection in antibody deficient patients. Eur J Microbiol Immunol (Bp) (2014) 0.81
Exhaled breath analysis using electronic nose in cystic fibrosis and primary ciliary dyskinesia patients with chronic pulmonary infections. PLoS One (2014) 0.81
Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA). Diagn Pathol (2014) 0.81
Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis. Eur J Pediatr (2011) 0.77
Refining the continuum of CFTR-associated disorders in the era of newborn screening. Clin Genet (2016) 0.77
Repeatability and Diagnostic Value of Nasal Potential Difference in a Genetically Admixed Population. J Clin Med Res (2015) 0.75
Assessment of serology and spirometry and the combination of both to complement microbiological isolation for earlier detection of Pseudomonas aeruginosa infection in children with cystic fibrosis. BMC Pulm Med (2016) 0.75
Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis. BMC Pulm Med (2017) 0.75
Association between spirometry controlled chest CT scores using computer-animated biofeedback and clinical markers of lung disease in children with cystic fibrosis. Eur Clin Respir J (2017) 0.75
Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis. Lung (2017) 0.75
Body composition and lung function in children with cystic fibrosis and meconium ileus. Eur J Pediatr (2017) 0.75
Nano-sized transition-metal oxides as negative-electrode materials for lithium-ion batteries. Nature (2000) 7.29
In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother (1984) 3.66
GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob Agents Chemother (1980) 3.61
Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet (1991) 3.37
Pathogenesis of cystic fibrosis. Lancet (1993) 3.34
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet (1991) 3.26
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol (1997) 3.23
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J (2000) 3.14
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand (1983) 3.13
In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 3.05
Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (1999) 3.03
Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol (1996) 2.55
N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology (2001) 2.51
An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother (1986) 2.43
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut (2005) 2.20
Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol (1999) 2.20
Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother (1991) 2.09
Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. J Antimicrob Chemother (1990) 2.08
Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa. J Clin Microbiol (1989) 2.07
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand (1981) 2.03
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother (1987) 2.00
Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax (1992) 1.97
Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother (2004) 1.96
Reversible anionic redox chemistry in high-capacity layered-oxide electrodes. Nat Mater (2013) 1.96
Cross-reactions between Legionella pneumophila (serogroup 1) and twenty-eight other bacterial species, including other members of the family Legionellaceae. Infect Immun (1983) 1.93
[Guidelines on antibiotics in the Laegeforeningens Medicinfortegnelse 2000]. Ugeskr Laeger (2001) 1.93
Epidemiology of Pseudomonas aeruginosa infection in patients treated at a cystic fibrosis centre. Acta Pathol Microbiol Scand B (1980) 1.90
Crossed immunoelectrophoretic analysis of Legionella pneumophila serogroup 1 antigens. Infect Immun (1983) 1.89
Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J Antimicrob Chemother (2000) 1.85
Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol (2000) 1.85
Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun (1990) 1.81
An antigen common to a wide range of bacteria. I. The isolation of a 'common antigen' from Pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1980) 1.75
Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother (2003) 1.73
Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun (1983) 1.68
The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol (1986) 1.67
Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology (2000) 1.66
A reversible copper extrusion-insertion electrode for rechargeable Li batteries. Nat Mater (2003) 1.61
Immunological cross-reaction between antigen Tp-4 of Treponema pallidum and an antigen common to a wide range of bacteria. Acta Pathol Microbiol Immunol Scand B (1984) 1.60
Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis (1983) 1.56
Evaluation of a new identification system, Crystal Enteric/Non-Fermenter, for gram-negative bacilli. J Clin Microbiol (1995) 1.55
Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect (2011) 1.55
Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol (1999) 1.54
Identification of Corynebacterium amycolatum and other nonlipophilic fermentative corynebacteria of human origin. J Clin Microbiol (1998) 1.53
Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun (1990) 1.51
Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol (1993) 1.51
Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol (1988) 1.50
Differential and enrichment media for selective culture and recognition of yeast species from clinical material. Eur J Clin Microbiol Infect Dis (1995) 1.50
Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol (1987) 1.49
Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinable Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol (1988) 1.46
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros (2008) 1.46
An antigen common to a wide range of bacteria. 2. A biochemical study of a "common antigen" from Pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1980) 1.45
Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol (1994) 1.43
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother (1987) 1.42
Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax (1992) 1.42
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis (2001) 1.41
Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros (2009) 1.41
Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis. Infect Immun (1985) 1.41
A ten year review of colomycin. Respir Med (2000) 1.40
[Guidelines for antibiotic use in the Laegeforeningens Medicinfortegnelse 2000]. Ugeskr Laeger (2001) 1.39
Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology (2001) 1.39
Sexually transmitted infections among married women in Dhaka, Bangladesh: unexpected high prevalence of herpes simplex type 2 infection. Sex Transm Infect (2001) 1.39
Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit Care Med (1997) 1.39
[Decreasing vaccination rate--increasing risk of epidemics]. Ugeskr Laeger (1996) 1.38
Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence. Infect Immun (1984) 1.37
In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1981) 1.36
Interaction of Pseudomonas aeruginosa alkaline protease and elastase with human polymorphonuclear leukocytes in vitro. Infect Immun (1984) 1.34
Septicaemia caused by Rahnella aquatilis in an immunocompromised patient. Eur J Clin Microbiol Infect Dis (1988) 1.34
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS (2000) 1.33
Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis. Infect Immun (1983) 1.33
"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med (2009) 1.32
Terminal truncations in amp C beta-lactamase from a clinical isolate of Pseudomonas aeruginosa. Eur J Biochem (1999) 1.30
[Treatment of upper respiratory tract infections?]. Ugeskr Laeger (2000) 1.29
Production of N-acyl-L-homoserine lactones by P. aeruginosa isolates from chronic lung infections associated with cystic fibrosis. FEMS Microbiol Lett (2000) 1.28
Unsatisfactory performance of flow cytometer UF-100 and urine strips in predicting outcome of urine cultures. J Clin Microbiol (2001) 1.28
Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros (2011) 1.28
Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (1989) 1.28
Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. J Antimicrob Chemother (2002) 1.25
Polyagglutinability due to loss of O-antigenic determinants in Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand B (1985) 1.25
Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand (1987) 1.24
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother (2001) 1.24
AIDS-associated cryptococcal meningitis in Rwanda (1983-1992): epidemiologic and diagnostic features. J Infect (1999) 1.22
Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori. Clin Diagn Lab Immunol (1995) 1.22
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS (1994) 1.22
Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol (1998) 1.22
Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol (1999) 1.22
Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol (2002) 1.21
Sexually transmitted infections in a basic healthcare clinic in Dhaka, Bangladesh: syndromic management for cervicitis is not justified. Sex Transm Infect (1999) 1.21
Studies on hypersensitivity to bacterial antigens in intrinsic asthma. Allergy (1982) 1.20
Burkholderia (Pseudomonas) cepacia and cystic fibrosis: the epidemiology in Belgium. Acta Clin Belg (1996) 1.20
Clinical evaluation of the Copan ESwab for methicillin-resistant Staphylococcus aureus detection and culture of wounds. Eur J Clin Microbiol Infect Dis (2011) 1.20
Urinary tract infections in patients with spinal cord lesions: treatment and prevention. Drugs (2001) 1.19
Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region. Antimicrob Agents Chemother (1997) 1.19
Diagnosis and treatment of cystic fibrosis. Respiration (2000) 1.19
Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS (1993) 1.19
Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS (1997) 1.19
Hypergammaglobulinemic purpura in cystic fibrosis. Acta Paediatr Scand (1978) 1.18
Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect (1983) 1.18